Inhibition of CD40L with Frexalimab in Multiple Sclerosis
The CD40-CD40L pathway has been shown to be involved in the pathogenesis of multiple sclerosis. In this phase 2, double-blind, randomized trial, the effect of intravenous and subcutaneous anti-CD40L monoclonal antibody (Frexalimab) was evaluated in patients with multiple sclerosis compared with placebo. Frexalimab reduced the number of new gadolinium-weighted T1 lesions at 12 weeks compared […]